CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 61-72 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Beyond the Generic Tumor: Engineering Patient-Specific Immune Ecosystems for Cancer.

Anvari S; Naghinezhad J; Farokhi R; Rahnama MA; Hoseinzadeh S; Nikbakht M; Ahmadvand M

Jan 1, 2026

2026PubMedSupporting evidence

Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.

Sandholzer MT; Serger C; Liner AG; Uzun S; König D; Thut H; Ritschard R; Fürst JD; Zingg A; Mantuano NR; Kasenda B; Glatz K; Kappos EA; Matter M; Holbro A; Stenner F; Passweg J; Khanna N; Jeker L; Binder M; Zippelius A; Läubli H

Jan 1, 2026Cell reports. Medicine

2026PubMedSupporting evidence

A bio-orthogonally engineered probiotic-T cell chimera amplifies adoptive cell therapy through spatial DC-T cell immune licensing.

Shen J; Chu Y; Wang Y; Chen X; Ke Y; Huo D; Zhu J; Hong S; Qin S; Liu B; Liu Q

Jan 1, 2026Science bulletin

2026PubMedDirectly related

Advances in therapeutic approaches to gastric cancer.

Wang F; Wang ZX; Zhang YJ; He Y; Ji JF; Li YF; Qu XJ; Ba Y; Yuan SQ; Xu RH

Jan 1, 2026CA: a cancer journal for clinicians

2026PubMedDirectly related

Mechanism and clinical relevance of metabolic-immune cross-talk in pancreatic tumor microenvironment.

Malik JA; Jatavath M; Fishel ML; Bhatia R; Gautam SK

Jan 1, 2026Cytokine & growth factor reviews

2026PubMedDirectly related

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Chari A; Voorhees PM; Thertulien R

Jan 1, 2026Clinical advances in hematology & oncology : H&O

2026PubMedDirectly related

Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion.

He W; Cui K; Zeng Y; Yang W; Huang N; Zhu S; Farooq MA; Jiang D; Xu G

Jan 1, 2026Journal of translational medicine

2026PubMedDirectly related

[Molecular Diagnostics and Personalized Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)].

Semmler M; Casuscelli J; Zschäbitz S; Jann JC

Jan 1, 2026Aktuelle Urologie

2026PubMedDirectly related

FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.

Zhu Y; Xie X; Wu X; Ouyang S; Zhou Y; Wen K; Zhong Y; Chen Y; Wang H; Gao Y; Jiang L; Li H; Zhao W; Xu A; Bi E

Jan 1, 2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2026PubMedDirectly related

Engineering controllable CAR T-cell therapies: from binary safety switches to programmable immunity.

Smirnov S; Zaritskey Y; Salogub G; Fonin A

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Shahid Z; Yan J; Einarsdottir S; Usiak S; Perales MA; Park J; Usmani SZ; Stein E; Salles G; Jakubowski A; Papadopoulos E; Millard I; Giralt S; Shah GL; Kamboj M

Jan 1, 2026Haematologica

2026PubMedDirectly related

Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis.

Al-Mashdali AF; Abdelraof MO; Kaddoura R; Halfawi AM; Yousif MEM; Abdulgayoom M; Shah AR; Mohamed SF

Jan 1, 2026Immunotherapy